CVS Health’s stock (NYSE: CVS) is finally giving investors a reason to breathe easy. After a rocky 2024 marked by profit cuts and underperforming business segments, the company just dropped some seriously bullish news, and Wall Street is listening.<\/p>\n
<\/p>\n
On Thursday, CVS raised its full-year profit forecast, sending its stock surging more than 8% in premarket trading to $72.43. That jump builds on momentum from earlier in the year when February\u2019s earnings beat gave the first hint that a turnaround might be in motion.<\/p>\n
So, what\u2019s behind the renewed investor confidence? A mix of tighter cost controls, smarter operational moves, and a clear strategy from new CEO David Joyner, who took charge in October 2024. And if you\u2019re a CVS stockholder, or thinking about becoming one, there\u2019s a lot to unpack.<\/p>\n
A Much-Needed Comeback<\/b><\/p>\n
Let\u2019s not forget, CVS stock plunged over 40% last year, bruised by a string of profit warnings, shaky performance in its pharmacy and insurance segments, and overall investor fatigue. The company\u2019s once-pristine reputation as a healthcare giant was on the ropes.<\/p>\n
But now? We\u2019re seeing signs of a controlled rebound. For Q1 2025, CVS posted earnings of $2.25 per share, demolishing analyst estimates of $1.70. The company is now guiding full-year adjusted EPS to $6.00\u2013$6.20, up from a previous range of $5.75\u2013$6.00. That\u2019s a big confidence play, , nd investors are eating it up.<\/p>\n
What\u2019s Driving the Rebound?<\/b><\/p>\n Can CEO David Joyner Deliver?<\/b><\/p>\n Since taking over in October, Joyner has wasted no time cleaning house, e-shuffling top leadership and slashing costs. While it\u2019s early, the market clearly believes he\u2019s steering the ship in the right direction. If this earnings trend holds, CVS could finally be climbing out of its slump, and regaining its place as a reliable healthcare bet.<\/p>\n What to Watch Going Forward<\/b><\/p>\n\n